OTS - R-Biopharm announces test to detect monkeypox virus
2022. June 01. 14:25
Darmstadt, Germany, 1 June, 2022 (APA/OTS) - Test for research
purposes available soon - R-Biopharm AG, a leading and globally
operating biotechnology company based in Germany, will soon launch
a test for the detection of monkeypox virus. The real-time PCR
test, developed for research purposes (RUO), shall contribute to
track and control the epidemiological spread of the virus.
The product is expected to be available in approximately two to
three weeks under the name RIDA®GENE Monkeypox Virus RUO (part
number PG4915RUO). Like the test for the detection of the
SARS-CoV-2 virus, which was the first to be launched by a German
company for research purposes in February 2020 and was officially
approved for the diagnosis of SARS-CoV-2 in the fall of 2020 with
the CE mark, the real-time PCR test for the detection of monkeypox
virus will also be usable on all common real-time PCR instruments.
The uniform RIDA®GENE design also allows users to run this test
together with other RIDA®GENE products.
"R-Biopharm cares about the common good," says Dr. Andreas
Simons, Head of Product Management Clinical Diagnostics at
R-Biopharm. "That's why we went right to work on designing the
primers and probes needed for reliable detection when the first
report came from the Robert Koch Institute of a case of monkeypox
that was not related to a visit to Africa."
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany's
leading biotechnology companies. It considers itself as a pioneer
for health and quality of life. The company´s aspiration is to
provide the highest possible precision, safety, clarity and
certainty with excellent products and solutions - in prevention,
therapy and healing. Research and development at R-Biopharm has
developed agile processes in order to take on new challenges to
accompany a steadily growing world population into a new health era
with sustainable solutions.
As an internationally recognized leader, R-Biopharm stands for
the development of excellent technologies, products and solutions
in the fields of Clinical Diagnostics, Nutrition Care and Food and
Feed Analytics. R-Biopharm is the global market leader for test
systems in the field of allergen analysis. The biotechnology
company is known for its products that are of high importance for
human health. To this end, it unites development, production and
sales under one roof and is successfully represented in more than
120 countries worldwide - through 28 subsidiaries and 120
distributors. Founded in 1988, the family-run company employs a
total of around 1,300 people worldwide (690 at its headquarters in
Darmstadt) and was repeatedly recognized with the "Sustainability
Award" for sustainable and profitable growth. R-Biopharm is
cultivating a value-oriented corporate culture and management and
is family-run in the second generation. The Chairman of the board
of directors is Christian Dreher.
Picture: http://www.apimages.com
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/
https://r-biopharm.com/news-press/download-gallery/
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: +49 61 51 - 81 02-538
Mobile: +49 160 - 55 273 60
Fax: +49 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.